What is the coverage of Levofloxacin (a quinolone antibiotic) and other quinolones, such as Ciprofloxacin (ciprofloxacin) and Moxifloxacin (moxifloxacin)?

Quinolone Antibiotic Coverage

Levofloxacin Coverage

Levofloxacin provides comprehensive coverage against respiratory pathogens including S. pneumoniae (including penicillin-resistant strains), H. influenzae, M. catarrhalis, and atypical organisms (M. pneumoniae, C. pneumoniae, L. pneumophila), plus methicillin-sensitive S. aureus (MSSA), making it superior to ciprofloxacin for respiratory infections. 1, 2, 3

Gram-Positive Coverage

• S. pneumoniae: Enhanced activity including penicillin-resistant and multi-drug resistant strains (MDRSP), with <1% resistance in the US 2, 3, 4
• Methicillin-sensitive S. aureus (MSSA): MIC90 of 0.5 mg/L, making it effective for post-influenza bacterial pneumonia 5
• Streptococcus pyogenes: Fully covered 6
• Enterococcus faecalis: Many strains only moderately susceptible 6

Gram-Negative Coverage

• H. influenzae: Excellent activity including β-lactamase producing strains 1, 6
• M. catarrhalis: Excellent activity including β-lactamase producing strains 1, 6
• E. coli: 94.1% eradication rate in UTIs 7
• Klebsiella pneumoniae, Proteus mirabilis, Enterobacter cloacae: All covered 6
• Pseudomonas aeruginosa: Covered but less reliably than ciprofloxacin 6

Atypical Pathogen Coverage

• M. pneumoniae, C. pneumoniae, L. pneumophila: All covered with demonstrated clinical efficacy 1, 7

Key Limitations

• MRSA: NOT adequately covered 5
• Anaerobes: Limited activity 6

---

Ciprofloxacin Coverage

Ciprofloxacin should NOT be used for respiratory tract infections due to inadequate S. pneumoniae coverage and documented treatment failures in community-acquired pneumonia. 5, 2

Gram-Negative Coverage (Primary Strength)

• Pseudomonas aeruginosa: Superior activity compared to other quinolones, making it the preferred fluoroquinolone when Pseudomonas is suspected 1
• E. coli, Klebsiella, Proteus, Enterobacter: Excellent coverage 8
• H. influenzae, M. catarrhalis: Good coverage 8

Gram-Positive Coverage (Major Weakness)

• S. pneumoniae: INADEQUATE coverage with MIC90 of 1.0 mg/L (twice that of levofloxacin) and increasing resistance 5, 2
• MSSA: MIC90 of 1.0 mg/L (less potent than levofloxacin) 5
• MRSA: NOT covered 8

Appropriate Uses

• Urinary tract infections: Effective for complicated UTIs and pyelonephritis 6, 8
• Gastrointestinal infections: Including Salmonella, Shigella, Campylobacter 8
• Pseudomonas infections: Preferred fluoroquinolone when this pathogen is documented or highly suspected 1

Critical Contraindications

• Community-acquired pneumonia: Multiple guidelines explicitly state ciprofloxacin should NOT be used 5, 2
• Acute bacterial sinusitis: Not recommended as monotherapy due to pneumococcal coverage gaps 5

---

Moxifloxacin Coverage

Moxifloxacin provides the most potent Gram-positive coverage among quinolones with an MIC90 of 0.12 mg/L against MSSA, plus comprehensive respiratory pathogen coverage including anaerobes. 5, 9

Gram-Positive Coverage (Superior)

• S. pneumoniae: Excellent activity including multi-drug resistant strains (MDRSP) 9
• MSSA: MIC90 of 0.12 mg/L (most potent among quinolones) 5
• Streptococcus pyogenes, S. agalactiae: Fully covered 9

Gram-Negative Coverage

• H. influenzae, M. catarrhalis: Excellent coverage 9
• E. coli, Klebsiella pneumoniae, Enterobacter cloacae: Covered 9
• Pseudomonas aeruginosa: NOT reliably covered (major limitation vs. ciprofloxacin) 9

Anaerobic Coverage (Unique Advantage)

• Bacteroides fragilis, B. thetaiotaomicron: Covered 9
• Clostridium perfringens, Peptostreptococcus species: Covered 9
• Fusobacterium, Prevotella species: Covered 9

Atypical Pathogen Coverage

• C. pneumoniae, M. pneumoniae: Excellent activity 9

Key Limitations

• Pseudomonas: Inadequate coverage limits use in nosocomial pneumonia 9
• MRSA: NOT adequately covered 5

---

Clinical Decision Algorithm

For Respiratory Tract Infections

1. Community-acquired pneumonia: Use levofloxacin 750 mg daily OR moxifloxacin 400 mg daily; NEVER ciprofloxacin 2
2. Nosocomial pneumonia with Pseudomonas risk: Use ciprofloxacin OR combine levofloxacin with anti-pseudomonal β-lactam 1, 2
3. Acute bacterial sinusitis: Use levofloxacin OR moxifloxacin; avoid ciprofloxacin monotherapy 5
4. Acute exacerbation of COPD: Levofloxacin OR moxifloxacin preferred 5

For Urinary Tract Infections

1. Complicated UTI/pyelonephritis: Levofloxacin 750 mg daily for 5 days OR ciprofloxacin 500 mg twice daily for 7-14 days 6, 8
2. Chronic bacterial prostatitis: Levofloxacin 500 mg daily for 28 days (equivalent to ciprofloxacin) 6

For Skin/Soft Tissue Infections

1. Complicated infections: Levofloxacin 750 mg daily for 7-14 days 6
2. MSSA suspected: Levofloxacin OR moxifloxacin (moxifloxacin has superior MSSA activity) 5

For Suspected Pseudomonas

1. Any infection with documented or high-risk Pseudomonas: Ciprofloxacin is the preferred fluoroquinolone 1

---

Common Pitfalls to Avoid

• Never use ciprofloxacin for pneumonia or sinusitis: This results in 20-25% bacteriologic failure rates due to inadequate pneumococcal coverage 5, 2
• Avoid fluoroquinolones if recent exposure: Previous fluoroquinolone use within 3 months precludes empiric use due to resistance risk 1
• Don't use moxifloxacin for Pseudomonas: It lacks adequate anti-pseudomonal activity 9
• Recognize MRSA limitations: No fluoroquinolone adequately covers MRSA; add vancomycin or linezolid when MRSA is suspected 5
• Beware of resistance patterns: Macrolide resistance in S. pneumoniae is 12-19% and tetracycline resistance is 5-8%, making fluoroquinolones valuable alternatives 5